Innovative Approach and Promising Data Drive Buy Rating for Aura Biosciences
I'm PortAI, I can summarize articles.
Evercore ISI analyst Jonathan Miller maintains a Buy rating for Aura Biosciences due to its innovative approach and promising early data. Aura's unique mechanism targets tumor cells in early-stage indications, offering new treatment options for conditions like bladder cancer and uveal melanoma. Despite competition, Aura's progress in uveal melanoma presents a compelling investment opportunity. H.C. Wainwright also reiterates a Buy rating with a $22 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments